LARIMAR THERAPEUTICS, INC. (LRMR) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -172.60M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-172.60M | (m) |
| 2026-03-31 | (m) | $-166.00M | (m) |
| 2025-12-31 | (m) | $-165.67M | (m) |
| 2025-09-30 | (m) | $-132.00M | (m) |
| 2025-06-30 | (m) | $-99.79M | (m) |
| 2025-03-31 | (m) | $-95.23M | (m) |
| 2024-12-31 | (m) | $-80.60M | (m) |
| 2024-09-30 | (m) | $-64.77M | (m) |
| 2024-06-30 | (m) | $-58.34M | (m) |
| 2024-03-31 | (m) | $-45.08M | (m) |
| 2023-12-31 | (m) | $-36.95M | (m) |
| 2023-09-30 | (m) | $-33.38M | (m) |
| 2023-06-30 | (m) | $-32.64M | (m) |
| 2023-03-31 | (m) | $-32.94M | (m) |
| 2022-12-31 | (m) | $-35.35M | (m) |
| 2022-09-30 | (m) | $-35.06M | (m) |
| 2022-06-30 | (m) | $-43.55M | (m) |
| 2022-03-31 | (m) | $-47.49M | (m) |
| 2021-12-31 | (m) | $-50.64M | (m) |
| 2021-09-30 | (m) | $-55.71M | (m) |
| 2021-06-30 | (m) | $-49.17M | (m) |
| 2021-03-31 | (m) | $-47.90M | (m) |
| 2020-12-31 | (m) | $-42.48M | (m) |
| 2020-09-30 | (m) | $-56.63M | (m) |
| 2020-06-30 | (m) | $-54.98M | (m) |
| 2020-03-31 | (m) | $-35.89M | (m) |
| 2019-12-31 | (m) | $-45.41M | (m) |
| 2019-09-30 | (m) | $-52.73M | (m) |
| 2019-06-30 | (m) | $-54.88M | (m) |
| 2019-03-31 | (m) | $-58.52M | (m) |
| 2018-12-31 | (m) | $-61.37M | (m) |
| 2018-09-30 | (m) | $-59.88M | (m) |
| 2018-06-30 | (m) | $-57.40M | (m) |
| 2018-03-31 | (m) | $-54.97M | (m) |
| 2017-12-31 | (m) | $-52.03M | (m) |
| 2017-09-30 | (m) | $-49.38M | (m) |
| 2017-06-30 | (m) | $-51.47M | (m) |
| 2017-03-31 | (m) | $-53.15M | (m) |
| 2016-12-31 | (m) | $-57.88M | (m) |
| 2016-09-30 | (m) | $-70.61M | (m) |
| 2016-06-30 | (m) | $-75.82M | (m) |
| 2016-03-31 | (m) | $-78.55M | (m) |
| 2015-12-31 | (m) | $-74.29M | (m) |
| 2015-09-30 | (m) | $-62.04M | (m) |
| 2015-06-30 | (m) | $-56.85M | (m) |
| 2015-03-31 | (m) | $-45.49M | (m) |
| 2014-12-31 | (m) | $-36.48M | (m) |
| 2014-09-30 | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) |
| 2013-12-31 | (m) | $-14.03M | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) |
| 2012-12-31 | (m) | $-13.88M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |